News

Abbott Laboratories CEO calls post-earnings stock decline ‘a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Crain's Chicago Business2d
Abbott falls on outlook cut, sees $200 million tariff impact
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Abbott Laboratories falls after setting Q3 outlook below consensus
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
Abbott Earnings Beat Forecasts. Why the Stock Is Having Its Worst Day Since 2021.
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott flags over $1 billion hit in 2025 from tariffs, COVID test decline
Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign aid freeze.
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Abbott Labs Pares Outlook After Profit, Sales Gains
The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.
Should You Buy Abbott Stock At $135?
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
Abbott upgraded to Buy at Jefferies despite underwhelming outlook
Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...